Cerebra is excited to announce that Andre Puleo has joined our team as Business Development Manager. Andre will work to bring Cerebra and Odds Ratio Product (ORP) to the U.S. Clinical Marketplace. With over 25 years of experience in Sleep Medicine, as an RPSGT at the Hospital of the University of Pennsylvania and Children’s Hospital…
Read MoreNew Insights and Potential Clinical Implications of the Odds Ratio Product (ORP) October 24, 2023: Winnipeg, MB. Sleep has traditionally been analyzed in discrete stages assigned every 30 seconds based on visual feature detection. The Odds Ratio Product (ORP) measures wake/sleep state on a continuous scale leveraging the entirety of the electroencephalographic (EEG) signals. Simply…
Read MoreNewly launched MY Sleep Scoring API provides free access to leading sleep analysis metric, accelerating research into the clinical management of disrupted sleep. September 19, 2023: Winnipeg, MB Poor quality sleep doesn’t just make us feel tired, slow, and grumpy, it may also lead to major physical and mental health problems. Understanding sleep quality’s impact…
Read MoreWinnipeg, MB – Cerebra Medical Ltd., in partnership with IDUN Technologies AG and Pilotfish Nederland BV, is pleased to announce Eurostars funding supporting the development of breakthrough sleep improvement technology. Combining Cerebra’s proprietary Odds Ratio Product (ORP) sleep depth, IDUN’s leading in-ear brain interface technology, and Pilotfish’s design expertise, the project “Personalised Sleep Recovery Platform”…
Read MoreSomnoware announced today that the company is partnering with Cerebra Medical to integrate Cerebra’s autoscoring technology, MY Autoscoring, into the Somnoware platform. This partnership will enable automated sleep study scoring directly within the Somnoware platform. To learn more about this partnership, view the press release here
Read MoreHome grown technology supporting pandemic recovery January 17, 2023: Winnipeg, Manitoba. Cerebra, a Winnipeg based medical technology company advancing sleep disorder diagnostics, has entered into a contract with The Government of Manitoba under a Request for Supply Arrangement (RFSA) for the Provision of Diagnostic Services. Through the arrangement, Cerebra will work closely with the Province…
Read MoreWinnipeg, Canada — Cerebra Medical Ltd., a Canadian technology company transforming the future of sleep disorder diagnosis and therapy, announced today it has received 510(k) market clearance from the US Food and Drug Administration (FDA) for its Cerebra Sleep System; a lab quality in-home polysomnography (PSG) that is fully self-applied by the patient, without the…
Read MoreEkosi Health, a Canadian Indigenous-owned health care provider with expertise in clinical cannabinoid therapy has partnered with Cerebra, a Winnipeg based MedTech start-up revolutionizing sleep disorder diagnosis to advance the science of cannabinoid therapy and sleep. While there is promising preliminary evidence on the positive impact of cannabinoid therapies for sleep improvement, results to date…
Read MoreFirst of its kind sleep measurement tool to help simplify diagnostic process for physicians Innovative research from leading sleep scientists Dr. Magdy Younes and associates using novel EEG metric Odds Ratio Product (ORP) as a measure of sleep quality has revealed new insights into clinical symptoms of sleep disorders not detected through conventional metrics.…
Read MoreTeam of leading sleep scientists win the American Academy of Sleep Medicine award by using advanced sleep analytics based on ORP June 15, 2021: Winnipeg, Manitoba. A team of leading sleep scientists led by Dr. Amy Bender of Cerebra Health (Cerebra), a leader in sleep science, has won the inaugural American Academy of Sleep…
Read More